Zhang C, Zhang H, Huang L, Zhu S, Xu Y, Zhang X
Molecules. 2018; 23(11).
PMID: 30463393
PMC: 6278378.
DOI: 10.3390/molecules23113036.
van Wilgenburg B, Moore M, James W, Cowley S
PLoS One. 2014; 9(1):e86071.
PMID: 24465876
PMC: 3899108.
DOI: 10.1371/journal.pone.0086071.
Tosi P, Benoist H, Nicolau C
J Fluoresc. 2013; 1(2):141-6.
PMID: 24242964
DOI: 10.1007/BF00865210.
Matthias L, Azimi I, Tabrett C, Hogg P
J Biol Chem. 2010; 285(52):40793-9.
PMID: 20974843
PMC: 3003380.
DOI: 10.1074/jbc.M110.190579.
Xiang S, Kwong P, Gupta R, Rizzuto C, Casper D, Wyatt R
J Virol. 2002; 76(19):9888-99.
PMID: 12208966
PMC: 136507.
DOI: 10.1128/jvi.76.19.9888-9899.2002.
Amino acid substitutions in the V domain of nectin-1 (HveC) that impair entry activity for herpes simplex virus types 1 and 2 but not for Pseudorabies virus or bovine herpesvirus 1.
Martinez W, Spear P
J Virol. 2002; 76(14):7255-62.
PMID: 12072525
PMC: 136344.
DOI: 10.1128/jvi.76.14.7255-7262.2002.
Structural features of nectin-2 (HveB) required for herpes simplex virus entry.
Martinez W, Spear P
J Virol. 2001; 75(22):11185-95.
PMID: 11602758
PMC: 114698.
DOI: 10.1128/JVI.75.22.11185-11195.2001.
Localization of a binding site for herpes simplex virus glycoprotein D on herpesvirus entry mediator C by using antireceptor monoclonal antibodies.
Krummenacher C, Baribaud I, Ponce de Leon M, Whitbeck J, Lou H, Cohen G
J Virol. 2000; 74(23):10863-72.
PMID: 11069980
PMC: 113165.
DOI: 10.1128/jvi.74.23.10863-10872.2000.
Mutational analysis of the virus and monoclonal antibody binding sites in MHVR, the cellular receptor of the murine coronavirus mouse hepatitis virus strain A59.
Wessner D, Shick P, Lu J, Cardellichio C, Gagneten S, Beauchemin N
J Virol. 1998; 72(3):1941-8.
PMID: 9499047
PMC: 109486.
DOI: 10.1128/JVI.72.3.1941-1948.1998.
Structure-based design of immunologically active therapeutic peptides.
Murali R, Greene M
Immunol Res. 1998; 17(1-2):163-9.
PMID: 9479578
DOI: 10.1007/BF02786441.
RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE).
Schols D, Proost P, Van Damme J, De Clercq E
J Virol. 1997; 71(10):7300-4.
PMID: 9311806
PMC: 192073.
DOI: 10.1128/JVI.71.10.7300-7304.1997.
Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding.
Hsu E, Dorig R, Sarangi F, Marcil A, Iorio C, Richardson C
J Virol. 1997; 71(8):6144-54.
PMID: 9223509
PMC: 191875.
DOI: 10.1128/JVI.71.8.6144-6154.1997.
Role of CD4 epitopes outside the gp120-binding site during entry of human immunodeficiency virus type 1.
Simon J, Stumbles P, Signoret N, Somoza C, Puklavec M, Sattentau Q
J Virol. 1997; 71(2):1476-84.
PMID: 8995673
PMC: 191204.
DOI: 10.1128/JVI.71.2.1476-1484.1997.
Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding.
Wu H, Myszka D, Tendian S, Brouillette C, Sweet R, Chaiken I
Proc Natl Acad Sci U S A. 1996; 93(26):15030-5.
PMID: 8986758
PMC: 26350.
DOI: 10.1073/pnas.93.26.15030.
Residue Trp-48 of Tva is critical for viral entry but not for high-affinity binding to the SU glycoprotein of subgroup A avian leukosis and sarcoma viruses.
Zingler K, Young J
J Virol. 1996; 70(11):7510-6.
PMID: 8892869
PMC: 190818.
DOI: 10.1128/JVI.70.11.7510-7516.1996.
Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.
Chirmule N, Pahwa S
Microbiol Rev. 1996; 60(2):386-406.
PMID: 8801439
PMC: 239449.
DOI: 10.1128/mr.60.2.386-406.1996.
Identification of a ligand-binding site in an immunoglobulin fold domain of the Saccharomyces cerevisiae adhesion protein alpha-agglutinin.
de Nobel H, Lipke P, Kurjan J
Mol Biol Cell. 1996; 7(1):143-53.
PMID: 8741846
PMC: 278619.
DOI: 10.1091/mbc.7.1.143.
Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.
Berube P, Barbeau B, Cantin R, Sekaly R, Tremblay M
J Virol. 1996; 70(6):4009-16.
PMID: 8648738
PMC: 190279.
DOI: 10.1128/JVI.70.6.4009-4016.1996.
Antiviral effects of different CD4-immunoglobulin constructs against HIV-1 and SIV: immunological characterization, pharmacokinetic data and in vivo experiments.
Langner K, Niedrig M, Fultz P, Anderson D, Reiner G, Repke H
Arch Virol. 1993; 130(1-2):157-70.
PMID: 8503781
DOI: 10.1007/BF01319004.
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.
Cao J, Bergeron L, Helseth E, Thali M, Repke H, Sodroski J
J Virol. 1993; 67(5):2747-55.
PMID: 8474172
PMC: 237598.
DOI: 10.1128/JVI.67.5.2747-2755.1993.